This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Cefdinir
Description: Rocephrin is a third generation cephalosporin antibiotic. Third generation cephalosporins have greater Gram-(-) activity than first or second generation cephalosporins. Good activity is observed against streptococci and enteric Gram-(-) rods. Moderate activity is observed against methicillin sensitive strains of Staphyloccocus aureus, and relatively modest activity against Pseudomonas, anaerobes, and methicillin-resistant S. aureus.
Medicis and Abbott
On May 10, 2001, Abbott Laboratories and Medicis Pharmaceutical announced an exclusive agreement for Medicis to promote Omnicef (cefdinir) capsules for treatment of uncomplicated skin and skin structure infections.
Under the terms of the agreement, Omnicef capsules will be promoted to dermatologists and podiatrists in the U.S. exclusively by Medicis; marketing to primary care physicians and pediatricians will remain with Abbott. Financial terms of the agreement include an initial milestone payment to Abbott. Medicis will receive revenue from prescriptions generated in the dermatology and podiatry categories. Medicis will begin to promote and sell Omnicef in the near future.
Medicis and Valeant
In September 2012, Valeant and Medicis announced that they entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Medicis for $44.00 per share in cash. The combined company's...See full deal structure in Biomedtracker
Partners: Valeant Pharmaceuticals International, Inc.
Pink Sheet Abbott To Defend Omnicef Patents
Pink Sheet Patheon halts Omnicef manufacturing
Additional information available to subscribers only: